Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|November 1, 2009
- Applied Clinical Trials-11-01-2009
- Volume 0
- Issue 0
Applied Clinical Trials Digital Edition - November 2009
GLOBAL TRIALS : South Africa?s Positioning Fosters Healthy Trial Landscape Croatia?s Dynamic Qualities CROs Must Manage Italy?s Regulatory Makeover EDC?s Evolution in Japan Also in this issue : Postmarketing Pushes Back Approvals, EU Regulators Increase Involvement, Site Shake-Out Benefits Those That Remain, Is in Silico Modeling the Economic Solution?
Advertisement
Articles in this issue
almost 17 years ago
Business and People Update November 2009almost 17 years ago
Conducting Trials in Croatiaalmost 17 years ago
Preparing for Postmarketalmost 17 years ago
EDC Acceptance in Japanalmost 17 years ago
To Market Faster In Silico Stylealmost 17 years ago
Is an Investigative Site Shake-Out Imminent?almost 17 years ago
Growth for Welsh Companiesalmost 17 years ago
South Africa Todayalmost 17 years ago
Health Issues Raise EU's Regulatory Profilealmost 17 years ago
Safety Requirements Slow New Drug ApprovalsAdvertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
5